A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study

The is a first clinical study for Oricell Therapeutics Inc. in the United States to evaluate the safety, PK, PD and preliminary efficacy of our anti-GPRC5D cell product (OriCAR-017) in subjects with relapsed/refractory multiple myeloma. RIGEL Study

Trial Details

NCT ID
NCT06271252
Phase
PHASE1
Sponsor
OriCell Therapeutics Co., Ltd.
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • OriCAR-017
Locations (sample)
  • Atlanta, Georgia, United States|33.749,-84.38798

Key Eligibility Criteria

  • Capable of giving signed informed consent
  • Subjects aged 18 to 75 years (inclusive) at Screening (signing the ICF).
  • Expected survival period is \>12 weeks.
  • Diagnosis of MM according to the IMWG criteria (2016 version).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →